In the last week, the market has been flat, but it is up 12% over the past year, with earnings expected to grow by 15% per annum over the next few years. Investing in penny stocks—though often seen as a niche area—can still offer growth opportunities, particularly when these stocks are supported by strong financial health. As we explore several penny stocks today, we’ll focus on those that combine balance sheet strength with long-term potential.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Waterdrop (WDH) |
$1.42 |
$517.18M |
★★★★★★ |
|
WM Technology (MAPS) |
$0.9386 |
$154.96M |
★★★★★★ |
|
Perfect (PERF) |
$2.34 |
$241.38M |
★★★★★★ |
|
Talkspace (TALK) |
$2.78 |
$456.77M |
★★★★★★ |
|
Tuniu (TOUR) |
$0.9326 |
$99.78M |
★★★★★★ |
|
Safe Bulkers (SB) |
$3.77 |
$384.69M |
★★★★☆☆ |
|
Sequans Communications (SQNS) |
$2.07 |
$52.57M |
★★★★★★ |
|
BAB (BABB) |
$0.85 |
$6.17M |
★★★★★☆ |
|
North European Oil Royalty Trust (NRT) |
$4.90 |
$45.95M |
★★★★★★ |
|
TETRA Technologies (TTI) |
$3.54 |
$467.09M |
★★★★☆☆ |
Click here to see the full list of 422 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to degrade disease-causing proteins, with a market cap of $121.42 million.
Operations: C4 Therapeutics generates its revenue primarily through its Pharmaceuticals segment, which reported $39.78 million.
Market Cap: $121.42M
C4 Therapeutics, Inc. is navigating a challenging landscape as it remains unprofitable with increasing losses over the past five years. Despite having no debt and short-term assets of US$232.5 million exceeding both short and long-term liabilities, the company faces volatility in its share price and was recently dropped from multiple Russell indices, which may impact investor sentiment. The firm reported a net loss of US$26.32 million for Q1 2025 but has a cash runway for nearly two years if current cash flow trends persist. An increase in authorized shares suggests potential future capital raising activities.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Sana Biotechnology, Inc. is a biotechnology company that specializes in developing engineered cells as medicines in the United States, with a market cap of approximately $913.50 million.
Operations: Sana Biotechnology, Inc. currently does not report any revenue segments.
